Veradermics (NYSE:MANE) Price Target Raised to $150.00

Veradermics (NYSE:MANE) had its price target lifted by Leerink Partners from $135.00 to $150.00 in a research report report published on Monday,Benzinga reports. The firm currently has an outperform rating on the stock.

A number of other research analysts also recently weighed in on the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Veradermics in a research note on Friday, August 21st. Citigroup reaffirmed a “buy” rating on shares of Veradermics in a research note on Tuesday, September 15th. B. Riley Financial upped their price objective on Veradermics from $170.00 to $204.00 and gave the company a “buy” rating in a report on Thursday, October 22nd. Needham & Company LLC increased their target price on Veradermics from $164.00 to $172.00 and gave the company a “buy” rating in a research note on Monday, October 19th. Finally, UBS Group set a $204.00 target price on Veradermics in a report on Thursday, October 22nd. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Veradermics presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.57.

Veradermics Price Performance

Shares of NYSE:MANE opened at $156.11 on Monday. Veradermics has a 1-year low of $32.00 and a 1-year high of $156.63. The business has a 50-day moving average price of $120.82 and a two-hundred day moving average price of $98.02.

Veradermics (NYSE:MANE) last issued its earnings results on Tuesday, November 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. On average, equities research analysts anticipate that Veradermics will post -2.87 earnings per share for the current year.

Insider Transactions at Veradermics

In related news, insider Timothy August Durso sold 43,500 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $107.82, for a total transaction of $4,690,170.00. Following the sale, the insider directly owned 78,142 shares in the company, valued at $8,425,270.44. This trade represents a 35.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Reid Alexander Waldman sold 67,500 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $107.86, for a total transaction of $7,280,550.00. Following the completion of the sale, the chief executive officer directly owned 170,824 shares in the company, valued at $18,425,076.64. This represents a 28.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 861,000 shares of company stock valued at $92,408,220 over the last quarter.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MANE. Nvwm LLC raised its position in Veradermics by 105.4% in the 3rd quarter. Nvwm LLC now owns 228 shares of the company’s stock valued at $28,000 after buying an additional 117 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Veradermics by 8.4% in the third quarter. Russell Investments Group Ltd. now owns 1,905 shares of the company’s stock worth $231,000 after purchasing an additional 147 shares in the last quarter. Private Advisor Group LLC boosted its holdings in Veradermics by 4.8% during the third quarter. Private Advisor Group LLC now owns 7,712 shares of the company’s stock worth $935,000 after purchasing an additional 352 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in Veradermics by 233.2% during the third quarter. Sterling Capital Management LLC now owns 633 shares of the company’s stock worth $77,000 after purchasing an additional 443 shares during the last quarter. Finally, Pictet Asset Management Holding SA grew its position in Veradermics by 22.0% in the third quarter. Pictet Asset Management Holding SA now owns 2,491 shares of the company’s stock valued at $302,000 after purchasing an additional 449 shares in the last quarter.

Key Veradermics News

Investors following MANE have been watching these news items:

• Positive Sentiment: Veradermics reported positive results from the 12-month Study 302 Part B evaluation of VDPHL01, its potential treatment for pattern hair loss. The clinical update appears to be a key catalyst, though the reports provided here do not include detailed efficacy figures. Veradermics stock rises on 12-month hair growth trial data Study 302 Part B results transcript
• Positive Sentiment: Third-quarter EPS was a loss of $0.50, but that was better than analysts’ expected loss of $0.59. The company also highlighted recent corporate and clinical progress. Third-quarter 2026 results and progress
• Negative Sentiment: Despite beating the estimate, Veradermics remained loss-making in the quarter, so investors will likely focus on clinical execution and the path toward commercialization. Q3 earnings snapshot

About Veradermics

Veradermics is a clinical-stage biopharmaceutical company focused on developing treatments for hair loss. Its lead candidate, VDPHL01, is an investigational oral formulation of minoxidil being studied for androgenetic alopecia, commonly known as male- or female-pattern hair loss. The company has described the treatment as designed for once-daily use. VDPHL01 remains under clinical investigation and is not an approved treatment. Veradermics is led by founder and Chief Executive Officer Reid Waldman, a physician specializing in dermatology.